Approval of inhaled insulin in Europe and United States

doi:10.1136/bmj.332.7543.730-b

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Bruce Charlesworth, head of RMRS and medical affairs (bruce.charlesworth@pfizer.com)

Pfizer Limited, Walton Oaks, Walton-on-the-Hill, Tadworth, Surrey KT20 7NS

EDITOR—We wish to respond to several points in the news item by Lenzer on the approval of inhaled insulin.1

Firstly, the article states that critics say that Exubera fails to control postprandial glucose presentations as well as subcutaneous insulin. In fact, in clinical trials Exubera is comparable or superior to subcutaneous human insulin in terms of postprandial glucose control.2^–4

Secondly, the article raises concerns about the pulmonary effects of Exubera. Pfizer has …